FDA to Study Whether the 'Safe' Pill Is Safe.

For years, the sales pitch for the abortion pill was that the science was settled. Now the settled science has a study schedule.

In a court-ordered filing on Oct. 7 in Louisiana's lawsuit over the mail-order rule, the Food and Drug Administration said its safety review of mifepristone will run into 2027. The agency expects to receive the results of a safety study in December 2026 and will issue a report after interpreting them — a final report no later than March 2027. The review, ordered by Health and Human Services Secretary Robert F. Kennedy Jr., compares a sample of 100,000 women who used mifepristone with a group who had surgical abortions, using a statistical data-mining method to hunt for safety risks not yet identified.

To be clear about what this is not: the review is ongoing. It is not a finding that the pill is unsafe, and no new restriction follows from a filing that says "we're still studying it." What it is, though, is the federal government formally scheduling homework on a drug whose defenders spent years insisting needed none.

The pill was sold as safer than routine drugs. The FDA approved it in 2000, reaffirmed it repeatedly, and in 2023 made mail-order dispensing permanent. Now the same agency needs until March 2027 to finish checking. The science wasn't settled; it was just unexamined on a deadline.

The study lands in December. The report lands by March. The punchline landed the moment the filing did.

The underlying reporting is filed in the Evidence Locker: Reuters (Oct. 8, 2026); Associated Press (Oct. 8, 2026).